Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiawei Guizhi Fuzi Decoction is a modified Traditional Chinese Medicine (TCM) herbal formula developed by the Affiliated Hospital of Yunnan University of Traditional Chinese Medicine (also known as the Yunnan Provincial Hospital of Traditional Chinese Medicine) for the treatment of rheumatoid arthritis (RA). The formula is an adaptation of the classic Guizhi Fuzi Decoction from the *Shanghan Lun*, which traditionally targets 'Cold-Dampness Obstruction' (Han Shi Bi Zu) patterns. This modified version incorporates additional botanical ingredients to enhance its anti-inflammatory, analgesic, and immunomodulatory properties. It is designed to dispel wind, eliminate dampness, warm the meridians, and relieve joint pain. Clinical research conducted by the developer indicates that the decoction can effectively reduce joint swelling, morning stiffness, and systemic inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) by modulating pro-inflammatory cytokine production and immune cell balance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jiawei guizhi fuzi decoction.